Journal
VACCINE
Volume 38, Issue 36, Pages 5851-5860Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2020.05.062
Keywords
Developing countries; Vaccine manufacturing; Regulatory convergence; Market intelligence; Biotechnology innovation
Categories
Funding
- Bausch Stroebel
- Bioengineering
- Biozeen
- Bosch
- GEA Group
- GE Healthcare
- Gihon
- InDevR
- Merck Group
- Stevanato Group
- Rommelag
- Sartorius
- Temptime Corporation
- Tofflon
- Univercells
- Bill & Melinda Gates Foundation, United States [OPP1204376]
- Bill and Melinda Gates Foundation [OPP1204376] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
The Developing Countries' Vaccine Manufacturers Network, joined by global health organizations, held its 20th meeting celebrating two decades of vaccine innovations for global public good. Health leaders from industry, academia and global health organizations reviewed efforts to accelerate innovation, improve access to vaccines, overcome inequalities and strengthen technological and public-health management capabilities. Discussion topics included World Health Organization's immunization strategy, Pan American Health Organization's system-strengthening efforts, Gavi's evaluation of vaccine coverage in middle income countries and developments on public-market intelligence. Health market trends, delivery gaps, integration of system-wide needs, costs and benefits, and implications for stakeholder decision-making were areas of focus. Novel thinking was discussed on integration of policy, financing, regulatory pathways and alignment of innovation priorities to improve efficiency in vaccine development pathways. The Vaccine Innovation Prioritization Strategy collaboration presented nine global innovation priorities, and many other partners and members presented updates on their priorities. Novel technologies and platforms, such as RNA-based vaccines, adenoviral vectors, bioconjugation, blow-fill-seal and two-dimensional barcodes, provided opportunities to accelerate vaccine innovations. Challenges in planning and operations at global level included those in health security, polio eradication, re-emergence of diseases, disparities between forecasts and orders and heterogeneous regulatory requirements. Manufacturers were urged to accelerate innovation and prequalification of high-impact vaccines, such as pneumococcal, human papillomavirus and rotavirus vaccines, to strengthen immunization globally. (C) 2020 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available